Innovator Capital was founded to assist Life Science companies and entrepreneurs. Mungo Park, Innovator’s founder and Executive Chairman, has over 30 years of experience in this industry beginning in 1978 with the initial public offering of Genentech. He has been involved subsequently in similar transactions with companies such as Amgen, Biogen, Genzyme and over 50 other transactions of varying types.
The firm takes on a small number of new Life Science projects each year; invariably these are disease indication specific and where the companies can benefit from Innovator’s wealth of strategic, intellectual property, finance and sector knowledge.
From a technology perspective the firm works across the Life Sciences and Healthcare domains, from software to small molecule pharmaceuticals. Innovator will typically engage at an earlier stage of technology and commercial development than larger investment banks. Ensuring minimal dilution of shareholder value, during the often highly capital intensive research phase of new technologies, is a key Innovator Capital objective.
The firm is able to leverage a network of relationships established over 30 years; these relationships include patient associations, key opinion leaders, venture capitalists, private equity investors, specialty pharma corporates, multinationals and informed family offices.
The objective is to ensure always that optimal business and patient outcomes are achieved.